Thursday, November 19, 2026

AI Is Entering Drug Discovery Just as Investors Question AI Spending: What Biotech's Q4 2026 Disclosures Show

Biotechs are reporting real progress while AI is being built into the work, but the AI funding mood turned cautious in late October. Via News checked company releases and SEC-sourced Incyte figures. The sourced evidence for an AI-biotech link is thin, and we say where.

Via News Editorial Team

November 19, 2026

This article was generated by AI. Built from the source documents listed below. How we work

AI Is Entering Drug Discovery Just as Investors Question AI Spending: What Biotech's Q4 2026 Disclosures Show
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The AI claim is real, but small

The most direct AI-in-biology item in our verified record is an announcement from Radical Numerics, which said AI-designed viruses have treated the startup's first patient, with an experimental treatment aimed at drug-resistant E. coli.1 It is a company statement relayed in a newsletter digest, and a single patient is not a trial result. It shows that AI-designed biological agents have reached a human. It does not show that they work.

That caution matters because the rest of the story is about money. Between October 30 and November 1, 2026, three events pointed to a colder mood toward AI spending. A $1 trillion tech selloff deepened fears of an AI bubble, as big AI bills and weak earnings spooked investors, and the Nasdaq 100 had its worst day since June.2 The next day OpenAI cut its funding target by $10 billion.3 On November 1, Binance users withdrew $3.6 billion when the exchange reopened after a hack.4 The Binance item is a crypto event, not an AI one. We list it only because it fell in the same three days.

The Via News reading, which is our analysis and not a sourced finding, is that biotech companies using AI tools are not insulated from this mood. The records here show the mood changed. They do not show how it has moved the funding of any specific biotech, and we found no source that measures that link. Treat it as a hypothesis.

What the pipelines actually reported

The clinical news is the best-evidenced part of the dossier, and most of it has nothing to do with AI.

Scribe Therapeutics reported third quarter 2026 results on November 12. It said enrollment continues in the first-in-human Phase 1 trial of STX-1150, an epigenetic silencing therapy for lowering LDL cholesterol, with initial clinical data expected in the first half of 2027.5 It also said it expanded its collaboration with Sanofi.5 Scribe argues that current LDL-lowering treatments are limited by poor persistence, with studies showing 50% to 70% of patients stopping within one year.5 It also says people with naturally occurring PCSK9 loss-of-function variants have been reported to have 28% lower mean LDL-C and up to 88% lower coronary heart disease risk, and that STX-1150 aims to mimic that protection.5 These are the company's own claims about a trial that has not yet produced data.

Vor Bio reported final two-year results from the Phase 3 TELIGAN trial of telitacicept in IgA nephropathy, a kidney disease. The annualized kidney-function slope was -0.6 versus -5.7 mL/min/1.73 m²/year for placebo, a treatment difference of 5.1 (p<0.001).6 The company reported 89% and 81% reductions in the risk of confirmed declines of at least 30% and 40% in kidney function, and a favorable safety profile.6 This is a company press release, but it is a full Phase 3 readout with a stated significance level, which is stronger evidence than most of what appears below.

Akari Therapeutics is further back. Its CEO said Akari is advancing toward a planned Phase 1 for AKTX-101 in mid-2027, and described patients whose cancers no longer respond to antibody drug conjugates (ADCs) as a significant, growing unmet need.7 The company called this an exclusive opportunity for its novel payload, which current and most future ADCs will not be able to access.7 That is a positioning statement from a company with no human data yet.

Cash runways: Incyte's checked numbers

For a hard look at how a larger biotech funds its pipeline, we have SEC-sourced figures for Incyte Corporation. Its cash stood at $3.28 billion at the end of Q3 2026, down from $3.98 billion at the end of Q2 2026.8 Both figures are well above the $2.46 billion reported for Q3 2025 and the $1.30 billion for Q3 2024.8 Cash is lumpy. Our dossier has no cash-flow statement or note explaining the quarter-to-quarter swing, so we cannot say why it fell. Incyte's cost of revenue was $108.7 million in Q3 2026, against $99.0 million a year earlier.8 The dossier has no market-capitalization figure for Incyte, so we cannot tell you how large that cash pile is next to the company's total value.

The narrative we were given also says Incyte presented pancreatic cancer combinations at ESMO and develops treatments for PD-1 resistant head and neck cancer. Our graph records the second point, but we found no source document in the dossier for the ESMO claim, so we do not report its details.

Where revenue is already arriving

Commercial-stage evidence is clearer. BioArctic said Leqembi sales reported by its partner Eisai totaled JPY 29.3 billion in Q2 2026, which produced a royalty to BioArctic of SEK 179 million, up about 10 percent from Q2 2025.9 That comparison is flattered by timing: Q2 2025 included a one-time stockpiling effect in China of around JPY 5.3 billion. BioArctic says that excluding it, royalty revenues in Q2 2026 grew approximately 43 percent year over year.9 We report both numbers because they tell different stories. The headline growth is 10 percent, and the underlying growth, on the company's own adjustment, is 43 percent. The dossier also links Eli Lilly to the large pharma competitive set, but contains no source figures on Lilly's weight-loss demand, so we make no claim about it.

The reliability problem

One part of this dossier needs a warning label. A startup called Generation Lab says its treatment, 1 Generation, "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues."10 That is the company's wording, repeated in three MIT Technology Review newsletter items.10,11 The source describes the treatment as an injectable combination of two existing drugs, and the company's fact sheet is the origin of the claim.10 Our own measurement of MIT Technology Review items in this system found that only 6% of 16 checked claims held up, a small sample but a poor result. For comparison, 54% of 6,752 claims from the press-release feed behind the Scribe, Vor, Akari and BioArctic items held up. Neither number is high. They are a reminder that company statements, which is what most of this dossier consists of, need independent confirmation before anyone acts on them. We treat the Generation Lab claim as an unverified marketing statement.

What to watch

  • Scribe's first STX-1150 human data in the first half of 2027, the next test of its LDL-lowering claims.5
  • Whether the Radical Numerics patient result is followed by trial data rather than another announcement.1
  • Whether the cooler AI funding mood of late October persists, since OpenAI's lowered target and the selloff are the evidence for it so far.2,3
  • Incyte's next quarterly cash figure, to see whether the Q3 2026 drop was a one-off.8

Source documents

Via News is a conduit. We point to the source documents behind this report: we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleMotley Fool
    AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
  2. [2]News articleYahoo Finance· October 15, 2026
    Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
  3. [3]News articleMIT Technology Review
    A startup claims it’s found a drug to make your blood young
  4. [4]News articleYahoo Finance· July 27, 2026
    OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
  5. [5]News articleYahoo Finance· July 29, 2026
    Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
  6. [6]News articleYahoo Finance· November 12, 2026
    Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
  7. [7]News articleYahoo Finance· October 22, 2026
    Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
  8. [8]News articleMIT Technology Review
    The Download: AI’s trillion-dollar gamble and OpenAI’s biology data bid
  9. [9]News articleMIT Technology Review
    The Download: a secretive antiaging drug and joining virtual power plants
  10. [10]News articleMIT Technology Review
    The Download: computing’s next leap and permafrost’s climate threat
  11. [11]Press releaseGlobeNewswire· July 15, 2026
    Three Biotechs Deliver Catalysts to Watch
  12. [12]News articleNasdaq· July 29, 2026
    Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Built from 12 source documents from 5 publications, dated 15 Jul 2026 to 12 Nov 2026
  2. Published 19 Nov 2026
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
Via News Editorial Team

The Via News Editorial Team writes analysis and news from the Via News source-traceability system, under the editorial responsibility of L. Miguel Salvado, Editor. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. Articles generated with AI say so under the byline, as the EU AI Act requires.